BioVie Shares jump Premarket on Parkinson’s, Alzheimer’s Studies >BIVI
admin By Colin Kellaher Shares of BioVie Inc. rose sharply in premarket trading Tuesday after the…
Read MoreNeurodegenerative Disease Drugs
Roche says Phase 3 studies for Alzheimer’s drug failed to meet primary endpoints
Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of…
Read MoreBiogen and Eisai make plans to take another Alzheimer’s drug to the FDA
Biogen Inc. BIIB, -1.93% and Eisai Co. Ltd. 4523, +3.57% are getting closer to a…
Read MoreHere’s one thing that will cost less next year—what it means for Medicare beneficiaries
This article is reprinted by permission from NerdWallet. While inflation is pushing up prices for…
Read MoreGetting Medicare to cover Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
An experimental Alzheimer’s disease treatment developed by Eisai and Biogen that appears to slow cognitive…
Read MoreRegulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late…
Read MoreEisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and…
Read MoreAlzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug…
Read More
Cold sores and shingles may be linked to Alzheimer’s, new research indicates
Could cold sores plus shingles lead to Alzheimer’s? New research from Tufts and Oxford universities…
Read More